{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-009536","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.467191+00:00","generated_at":"2026-06-04T23:46:49.918006+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Propanc Biopharma raises $46,875 via convertible note at 35% discount and 8% interest","bullets":["Principal amount $50,000; purchase price $46,875; net proceeds for working capital.","Conversion price = 65% of lowest closing trade price over prior 10 trading days (35% discount).","Interest 8% per annum (16% on default); maturity March 1, 2024 (same as issuance date).","Prepayment rights within 180 days at 110% to 125% premium; no prepayment after 180 days.","Note issued under Regulation D, unregistered; subject to 4.99% beneficial ownership limitation."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-009536","json":"https://secwatch.observer/filing/0001493152-24-009536.json","markdown":"https://secwatch.observer/filing/0001493152-24-009536.md","text":"https://secwatch.observer/filing/0001493152-24-009536.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000149315224009536/0001493152-24-009536-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000149315224009536/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:46:49.918006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2744c2d2191fad6a5990812d4d2773aeb268ea48","claim":"Propanc Biopharma, Inc. incurred convertible notes of $50,000 with an investor at eight percent (8%) per annum, which may be increased to sixteen percent (16%) in maturing March 1, 2024.","evidence_excerpt":"Effective March 5, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $50,000 (the “Note”), for a purchase price of $46,875.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315224009536/0001493152-24-009536-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$50,000"},{"label":"Counterparty","value":"an investor"},{"label":"Rate","value":"eight percent (8%) per annum, which may be increased to sixteen percent (16%) in"},{"label":"Maturity","value":"March 1, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"1e27d116e480c97abfc232d6e5e32c8cc50d9caf","claim":"Propanc Biopharma, Inc. entered into Purchase Agreement with an investor valued at $50,000 (effective 2024-03-05).","evidence_excerpt":"Effective March 5, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $50,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315224009536/0001493152-24-009536-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an investor"},{"label":"Value","value":"$50,000"},{"label":"Effective","value":"2024-03-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}